Russia Quietly Changed Its Space Station Plans. Here's What That Means The proposed Russian Orbital Station will stick to a ...
Ultragenyx jumps after completing rolling BLA submission to the FDA for DTX401, an AAV gene therapy that could become the first approved treatment for GSDIa.
TipRanks on MSN
Ultragenyx completes BLA filing for GSDIa gene therapy
Ultragenyx Pharmaceutical ( ($RARE) ) just unveiled an update. On December 30, 2025, Ultragenyx Pharmaceutical announced it had completed the ...
The F-35 program closes 2025 under the shadow of a new report from the Pentagon‘s Inspector General: millions in payments ...
Artemis II will send astronauts around the moon in February-April 2026, marking NASA’s first crewed lunar mission in 53 years ...
NASA astronaut Zena Cardman processes bone cell samples inside the Kibo laboratory module's Life Science Glovebox. NASA 2025 ...
If approved, DTX401 will be the first therapy approved to treat the underlying cause of GSDIaNOVATO, Calif., Dec. 30, 2025 ...
A look at NASA’s Apollo 8 mission, its impact in 1968, and how Artemis 2 could shape the future of human spaceflight in 2026 ...
Murphy’s law worked hard in 2025.A year full of “what else can go wrong”, and then the wrong proceeds to make its way in, ...
I always get nostalgic when I come to Houston, the “Space City,” as I did for Saturday’s Texas Bowl between LSU and the ...
In commission-driven environments, anti-bribery and corruption (ABAC) violations don’t begin with overt misconduct. They ...
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced that it has completed the rolling submission of its Biologics License Application (BLA) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback